CircYAP1 inhibits osteosarcoma progression through the miR-135b-5p/FRK axis

IF 4.6 2区 综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES
Mingrui Du , Xuesan Zhang , Menglin Cong , Chengkui Cai , Qingxiang Zhang , Haixia Xin , Lanbo Yang , Qingqing Geng , Mingfu Shang , Zheng Zhang , Le Shen , Shusen Tan , Kang Han
{"title":"CircYAP1 inhibits osteosarcoma progression through the miR-135b-5p/FRK axis","authors":"Mingrui Du ,&nbsp;Xuesan Zhang ,&nbsp;Menglin Cong ,&nbsp;Chengkui Cai ,&nbsp;Qingxiang Zhang ,&nbsp;Haixia Xin ,&nbsp;Lanbo Yang ,&nbsp;Qingqing Geng ,&nbsp;Mingfu Shang ,&nbsp;Zheng Zhang ,&nbsp;Le Shen ,&nbsp;Shusen Tan ,&nbsp;Kang Han","doi":"10.1016/j.isci.2025.112858","DOIUrl":null,"url":null,"abstract":"<div><div>Circular RNAs (circRNAs) are implicated in the progression of various malignancies, including osteosarcoma. However, little is known about the role of circYAP1 in osteosarcoma. In the present study, the expression of circYAP1 was found to be downregulated in osteosarcoma tissues relative to adjacent normal tissues. Decreased circYAP1 expression was also found in metastatic osteosarcoma specimens relative to nonmetastatic specimens, and low circYAP1 group had a higher metastasis rate and more advanced clinical stage than high circYAP1 group. <em>In vitro</em> functional assays demonstrated the inhibitory effects of circYAP1 on osteosarcoma cell proliferation, invasion, and migration. Regarding the mechanism, circYAP1 acts as a competitive endogenous RNA (ceRNA) to sponge miR-135b-5p, whereas FRK is a direct target of miR-135b-5p. Finally, a tumor-suppressing role of circYAP1 was demonstrated in the orthotopic lung metastasis models. In conclusion, our data reveal a tumor-suppressing role of circYAP1 and circYAP1/miR-135b-5p/FRK axis in osteosarcoma, demonstrating potential therapeutic targets for osteosarcoma.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 7","pages":"Article 112858"},"PeriodicalIF":4.6000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iScience","FirstCategoryId":"103","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589004225011198","RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Circular RNAs (circRNAs) are implicated in the progression of various malignancies, including osteosarcoma. However, little is known about the role of circYAP1 in osteosarcoma. In the present study, the expression of circYAP1 was found to be downregulated in osteosarcoma tissues relative to adjacent normal tissues. Decreased circYAP1 expression was also found in metastatic osteosarcoma specimens relative to nonmetastatic specimens, and low circYAP1 group had a higher metastasis rate and more advanced clinical stage than high circYAP1 group. In vitro functional assays demonstrated the inhibitory effects of circYAP1 on osteosarcoma cell proliferation, invasion, and migration. Regarding the mechanism, circYAP1 acts as a competitive endogenous RNA (ceRNA) to sponge miR-135b-5p, whereas FRK is a direct target of miR-135b-5p. Finally, a tumor-suppressing role of circYAP1 was demonstrated in the orthotopic lung metastasis models. In conclusion, our data reveal a tumor-suppressing role of circYAP1 and circYAP1/miR-135b-5p/FRK axis in osteosarcoma, demonstrating potential therapeutic targets for osteosarcoma.

Abstract Image

CircYAP1通过miR-135b-5p/FRK轴抑制骨肉瘤进展
环状rna (circRNAs)与包括骨肉瘤在内的各种恶性肿瘤的进展有关。然而,circYAP1在骨肉瘤中的作用知之甚少。在本研究中,我们发现circYAP1在骨肉瘤组织中相对于邻近的正常组织表达下调。与非转移性骨肉瘤标本相比,转移性骨肉瘤标本中circYAP1的表达也有所降低,且circYAP1低表达组的转移率高于高表达组,且circYAP1高表达组的临床分期更晚。体外功能实验证明circYAP1对骨肉瘤细胞增殖、侵袭和迁移具有抑制作用。关于其机制,circYAP1作为竞争性内源性RNA (ceRNA)海绵miR-135b-5p,而FRK是miR-135b-5p的直接靶点。最后,在原位肺转移模型中证实了circYAP1的肿瘤抑制作用。总之,我们的数据揭示了circYAP1和circYAP1/miR-135b-5p/FRK轴在骨肉瘤中的肿瘤抑制作用,证明了骨肉瘤的潜在治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
iScience
iScience Multidisciplinary-Multidisciplinary
CiteScore
7.20
自引率
1.70%
发文量
1972
审稿时长
6 weeks
期刊介绍: Science has many big remaining questions. To address them, we will need to work collaboratively and across disciplines. The goal of iScience is to help fuel that type of interdisciplinary thinking. iScience is a new open-access journal from Cell Press that provides a platform for original research in the life, physical, and earth sciences. The primary criterion for publication in iScience is a significant contribution to a relevant field combined with robust results and underlying methodology. The advances appearing in iScience include both fundamental and applied investigations across this interdisciplinary range of topic areas. To support transparency in scientific investigation, we are happy to consider replication studies and papers that describe negative results. We know you want your work to be published quickly and to be widely visible within your community and beyond. With the strong international reputation of Cell Press behind it, publication in iScience will help your work garner the attention and recognition it merits. Like all Cell Press journals, iScience prioritizes rapid publication. Our editorial team pays special attention to high-quality author service and to efficient, clear-cut decisions based on the information available within the manuscript. iScience taps into the expertise across Cell Press journals and selected partners to inform our editorial decisions and help publish your science in a timely and seamless way.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信